DXCM — DexCom, Inc.

The July 30, 2026 Q2 print was the driver: revenue of $1.308B beat the ~$1.29B consensus, non-GAAP EPS of $0.70 beat $0.61, and the FY26 revenue guide moved up to $5.18-5.25B, sending shares up roughly 12%. Sell-side followed - Canaccord to $90, Piper Sandler to $95, Baird to $105 - with the consensus target at $89.71 and the recent average at $92.69 against a $83.03 price on 2026-09-13, and the analyst breakdown (1 strong buy, 41 buy, 8 hold, 2 sell) is firmly constructive. Dexcom was also named the first participant in the FDA's TEMPO digital-health pilot on July 22, 2026, and added former Stryker CFO Glenn Boehnlein to its board on September 10, 2026. The caveat: the stock is down 5.5% in the week and 8.6% in the month into 2026-09-13 with no company-specific news in the brief, which reads as profit-taking after a 29.3% six-month run rather than a change in the fundamental narrative.

The shape is decelerating top-line growth that has stabilized in the mid-teens while profitability inflects hard. Revenue YoY went from +2.0% in Q3 2024 to +21.6% in Q3 2025, then +13.1% in Q4 2025, +15.0% in Q1 2026 and +13.1% in Q2 2026 - a normalization off a blowout comparable, not a stall. Sequentially, revenue rose 9.8% from $1.192B in Q1 2026 to $1.308B in Q2 2026, the strongest sequential Q1-to-Q2 step in the dataset. Margins are the real story: gross margin expanded from 59.5% in Q2 2025 to 63.4% in Q2 2026, and operating margin from 18.4% to 24.3% - the fourth consecutive quarter above 20% versus 11.0% in Q1 2024. TTM operating margin is 22.9% and net margin 20.1%, with ROIC of 16.6% and ROE of 30.5%. Free cash flow was positive in all twelve quarters shown and TTM FCF is roughly $1.41B versus ~$571M a year earlier, while long-term debt was cut from $2.44B (Sept 2024) to $1.24B (June 2026) against $1.105B of cash. Two honest caveats: Q3 2025's $0.70 GAAP EPS came on net income of $283.8M versus operating income of just $242.5M, so a below-the-line gain flatters that quarter's trailing comparison; and Q2 2026 operating cash flow of $269.2M was 11% below Q2 2025's $303.0M on working-capital timing, even though TTM OCF is up ~77%.

Fair-to-modestly-cheap, but the historical anchor deserves skepticism. As of 2026-09-13 the stock trades at 32.1x TTM EPS of $2.605 and 31.1x the FY2026 consensus EPS of $2.668, with a PEG of 0.42, P/S of 6.3x and P/B of 12.2x. Against Dexcom's own five-year averages (P/E 107.8x, P/S 12.6x), shares look roughly half price - but that average was set when Dexcom's earnings base was a fraction of today's, so it is a weak anchor, which is exactly why the deterministic model excludes its own valuation overlay. The more useful comparison is growth-adjusted: ~13-15% revenue growth, ~19-27% forward EPS growth and a 20%+ net margin at 31x forward earnings is a modest premium to large-cap medtech (Abbott ~24x, Medtronic ~17x) and a discount to high-growth device peers (Boston Scientific ~35x). EV/EBITDA of 21.1x is reasonable for the quality. This is not a cheap stock in absolute terms - you are paying for execution - but it is not stretched relative to its own growth and cash generation.

The market is pricing in continued mid-teens growth and further margin expansion, not a re-rating. The evidence: a clear beat-and-raise on July 30, 2026 produced a ~12% single-day move, meaning the stock is far more sensitive to guidance revisions than to multiple expansion at this level. The risk case is mechanical - if revenue growth slips to high-single digits and the multiple compresses from ~31x to the low-20s (peer-medtech territory), you get $55-65 even on unchanged estimates. The upside case is equally mechanical: if G7 15-day sensor conversions approach the ~50% year-end target and Medicare/commercial coverage for non-insulin Type 2 patients keeps widening, FY2027 EPS estimates move from ~$3.15 toward $3.30 and support $95-105 without any multiple expansion. The Q2 beat plus the upward target revisions (Baird $105, Piper $95) say the burden of proof is on the bears right now, but the 8.6% one-month decline into 2026-09-13 shows how fast a 31x forward multiple gives back ground when momentum cools.

Range-bound pullback inside an intact uptrend. As of 2026-09-13, RSI(14) was 40.44 - cool but nowhere near oversold - with the price 6.41% below the 20-day SMA (roughly $88.7), 0.75% above the 50-day (roughly $82.4) and 16.31% above the 200-day (roughly $71.4). Returns: -5.54% over one week, -8.56% over one month, but +10.16% over three months and +29.25% over six months. Translation: the medium-term trend is up, the short-term trend is down, and price is sitting exactly on its 50-day support. Practically, that makes the 50-day ($82-83) the line that matters - holding it keeps the uptrend intact and offers a reasonable entry, while a decisive break opens the gap toward the $75-78 area (still well above the 200-day). Chasing at $92 in August was the wrong entry; the September pullback is a better one, but there is no capitulation signal here.

• Interest-rate path: with policy rates leaning toward cuts/stabilization in 2026, long-duration, high-ROIC medtech cash flows like Dexcom's (TTM FCF ~$1.41B, 20%+ net margin) see better institutional sponsorship and less multiple compression than in a hiking regime.
• Reimbursement expansion: widening Medicare and commercial coverage for CGM in non-insulin-using Type 2 diabetes is the single biggest multi-year volume driver, and it is a policy/coverage decision rather than a purely commercial one.
• Competitive intensity: Abbott (Libre/Lingo) is aggressively contesting both the retail pharmacy and DME channels, which keeps a ceiling on pricing and explains persistent low-end analyst targets ($64).
• GLP-1 adoption: a two-sided factor - slower long-run diabetes incidence is a theoretical headwind, while today's GLP-1 users are typically monitored more, not less, supporting near-term sensor volumes.
• Healthcare sector rotation and tariffs/supply chain: device makers have benefited from a procedure/adoption rebound, but sector rotation and any import-cost pressure on hardware components can move the group independently of company execution.
• Regulatory process risk/opportunity: the FDA TEMPO digital-health pilot (Dexcom selected July 22, 2026) could shorten approval cycles for software-driven features, but it also puts the company's regulatory execution in a higher-profile spotlight.

• Q3 2026 earnings (expected late October/early November 2026): the key numbers are U.S. G7 15-day sensor conversion progress toward the ~50% year-end target, international volume growth, and whether FY26 revenue guidance of $5.18-5.25B is raised again.
• Continued margin flow-through: Q2 2026's 24.3% operating margin and 63.4% gross margin, if sustained, would pull FY2027 EPS estimates above the current ~$3.15 trajectory and justify a higher multiple.
• FDA TEMPO digital-health pilot milestones: successful progression could accelerate feature launches and soften the regulatory timeline for future sensor/software generations.
• Further reimbursement expansion for non-insulin-using Type 2 patients in Medicare and commercial channels, which is the largest identifiable volume runway.
• Balance-sheet optionality: long-term debt cut to $1.24B with $1.105B cash and ~$1.4B TTM FCF leaves room for buybacks or bolt-on technology acquisitions.
• Sell-side target revisions after the Q2 beat (Canaccord $90, Piper $95, Baird $105) can themselves pull price toward the $89.71 consensus target if momentum returns.

• Valuation risk: at ~31x forward EPS on 2026-09-13, any deceleration in revenue growth below low-double-digits would compress the multiple quickly - a de-rating to the low-20s implies $55-65 without any estimate cut.
• Abbott and broader CGM price competition in retail pharmacy and DME channels, which pressures both gross margin and market share and is the core bear case behind the $64 low-end target.
• Dependence on reimbursement decisions: adverse Medicare/commercial coverage changes for non-insulin Type 2 patients would remove the largest identified growth driver.
• Execution risk on the G7 15-day conversion and international rollout - management has publicly targeted ~50% conversion by year-end 2026, and missing that would undermine the margin-expansion story.
• Earnings quality noise: Q3 2025 net income of $283.8M exceeded operating income of $242.5M on a below-the-line gain, and Q2 2026 operating cash flow fell 11% YoY on working capital - so headline EPS comparisons need to be read with care.
• Sensor accuracy, quality or recall events - any FDA action on a flagship product would hit revenue, reputation and the regulatory relationship simultaneously.

This is a genuinely good business trading at a fair-not-cheap price, and the recent pullback makes it more interesting than it looked in August. Dexcom converted from a money-losing growth story into a 20%-net-margin cash machine: operating margin went from 11.0% in Q1 2024 to 24.3% in Q2 2026, TTM FCF is ~$1.41B, debt has been halved, and revenue is still compounding at 13-15% with reimbursement expansion as a multi-year runway. The problem is you are paying ~31x forward earnings for that, in a market where Abbott is attacking pricing, so upside depends on continued beat-and-raise execution rather than multiple expansion. I lean positive over a 12-24 month horizon with fair value around $92, and I would treat the 50-day SMA (~$82-83) as the level that decides whether this pullback is an entry or the start of something worse.

I blended two forward-looking methods on FY2027 estimates rather than leaning on the distorted five-year average P/E. First, 29x forward EPS of ~$3.17 (FY2026 consensus EPS of $2.668 grown ~19% on mid-teens revenue growth, ~150bps of further operating-margin expansion and modest buybacks) = ~$91.9; 29x sits between large-cap medtech (~18-24x) and Dexcom's own 32x trailing multiple, appropriate for above-peer growth with 20%+ net margins. Second, 20x FY2027E EBITDA of ~$1.75B (FY2027E revenue ~$5.95B at a ~26% operating margin plus ~$200M D&A) gives ~$34.9B EV, less ~$0.14B net debt across ~380M shares = ~$91.6. The two methods converge at roughly $92, which I use as the fair value - about 11% above the $83.03 price on 2026-09-13.